AGP Executive Report
Last update: 9 hours agoPharma & Transplant Care: Hansa Biopharma has closed a €115m licensing deal with SERB for Idefirix (imlifidase), granting SERB exclusive development and commercialization rights across the EU, UK, Switzerland, Norway, Liechtenstein and MENA—aimed at helping highly sensitised kidney transplant patients. Osteoporosis Treatment Access: The European Commission has authorized CinnaGen’s Zandoriah (teriparatide) for adult osteoporosis, giving an EU-wide marketing platform that also covers Iceland, Liechtenstein and Norway. Antimicrobial Resistance Policy: EU/EEA pricing and reimbursement rules are being flagged as a potential lever against antimicrobial resistance, with a Nordic approach—cross-border antibiotic purchasing plus supplier remuneration—held up as a model. Heat & Public Health: A look back at the 2003 European heatwave (20,000+ deaths) raises alarms as air conditioning remains uncommon, leaving vulnerable groups at higher risk. Trade & Health-Adjacent Policy: EFTA and Vietnam have concluded a free trade agreement, including Liechtenstein, with provisions spanning goods, services, sanitary measures and investment—potentially shaping future cross-border healthcare supply chains. Local Health Workforce: UK medical students abroad, including in Liechtenstein-linked priority groups, have launched a legal challenge over NHS training place prioritisation.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
